Lobaplatin is a diastereometric mixture of platinum(II) complexes identified as a new platinum drug. Its antitumour activity results from the formation of DNA-drug adducts, mainly as GG and AG intra-strand cross-links.
LKB1/AAK1 dual inhibitor is an effective inhibitor against multi-kinase especially Pim-1 kinase, which has been newly found to be highly expressed in sorts of isolated human cancer cells. Kd: 35 nM/53 nM/75 nM/380 nM for Pim1/AKK1/MST2/LKB1.
Lisinopril Impurity F is an impurity of Lisinopril, a medication of the angiotensin-converting enzyme inhibitor class that is used to treat high blood pressure.
E7 Liquid Crystal Mixture, a crucial element in liquid crystal display (LCD) technology, plays a pivotal role in the functionality of electronic devices thanks to its exceptional dielectric anisotropy and steadfastness in operation.
Lipid 5 is a cationic amino lipid. LNPs incorporating Lipid 5 (from Sabnis et al.) demonstrated potent delivery of mRNA in primates but also were rapidly cleared from the body resulting in low toxicity.
Description of Linifanib: Linifanib is an orally bioavailable, small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as fms-related tyrosine kinase receptor-3 (FLT3).
Linezolid N-oxide is a derivative of Linezolid, an oxazolidinone antimicrobial that is used to treat infections against gram-positive bacteria, especially those that are drug-resistant. Linezolid works by inhibiting bacterial protein synthesis.
Lincomycin 2-Phosphate (Clindamycin Phosphate EP Impurity F) is an impurity of Clindamycin, which is a semi-synthetic antibiotic prepared from Lincomycin.
An impurity of Linagliptin. Linagliptin is a dipeptidyl peptidase-4 inhibitor with a hpyerglycemic activity. It was approved for the treatment of diabetes mellitus type 2.
An impurity of Linagliptin. Linagliptin is a dipeptidyl peptidase-4 inhibitor with a hpyerglycemic activity. It was approved for the treatment of diabetes mellitus type 2.
An impurity of Linagliptin, a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
An impurity of Linagliptin, a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
An impurity of Linagliptin, a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
An impurity of Linagliptin, a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
LIK066 is a potent sodium-glucose transporter 1 and sodium-glucose transporter 2 inhibitor originated by Novartis Pharmaceuticals Corporation IC50 with value of 22.0 nM against human SGLT1 and 0.5 nM against human SGLT2. In Apr 2016, Novartis completed a phase II trial for Type 2 diabetes mellitus in USA.
Ligustrazine Hydrochloride has certain protection effect on the vascular endothelium undergoing CPB, and lower excessive activation of coagulation reaction and inflammation reaction in patients undergoing CPB.
It is obtained from the delignification of lignocellulosic substances (wood, spent liquor, or other agricultural fiber source) by using an organic solvent.
Lignin, alkali can be used as a surface treatment agent for composites of natural fibers with petroleum based resins. It can be used as a biosorbent for potential applications in removing toxic metal ions from wastewater.
Lifitegrast is a Lymphocyte Function-Associated Antigen-1 (LFA-1) antagonist. It is used for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins, thus lessening overall inflammatory responses. It was initially developed by SARcode Bioscience, which was acquired by Shire in 2013.
Liensinine is extracted from the plantule of Nelumbo nucifera Gaertn. It is a kind of isoquinoline alkaloid, and it can antagonize the ventricular arrhythmias.
LH846 is a selective inhibitor of CK1δ, which displays no inhibitory activity at CK2. It inhibits CK1δ-dependent phosphorylation and degradation of PER1 protein, showing to lengthen the circadian period in U2OS cells, with minimal effect on amplitude.
L-Guanosine is a remarkable nucleoside widely utilized in exploring intricate neurological disorders, including Alzheimer's disease and dementia. Furthermore, L-Guanosine's pivotal role in RNA synthesis has propelled its prominence in the realm of antiviral drug development, specifically in the context of studying pernicious RNA viruses, such as hepatitis C.
An impurity of Thyroxine which is one of the two major hormones secreted by the thyroid gland and used to stimulate the consumption of oxygen and thus the metabolism of all cells and tissues in the body.
Levomilnacipran (brand name Fetzima) is an antidepressant approved for the treatment of major depressive disorder in the United States. It was developed by Forest Laboratories and Pierre Fabre Group, and was approved by the Food and Drug Administration in July 2013. Levomilnacipran is the levo-enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin-norepinephrine reuptake inhibitor (SNRI).
A natural, active form of folic acid used at the cellular level for DNA reproduction, the cysteine cycle and the regulation of homocysteine among other functions. It is a coenzymated form of folic acid and a more bioavailable alternative in dietary supplements. It has been proposed for treatment of cardiovascular disease.
An impurity of Levofloxacin, which is as efficacious as or more efficacious than that with ciprofloxacin in systemic as well as pyelonephritis infections in mice.
An impurity of Levofloxacin, which is as efficacious as or more efficacious than that with ciprofloxacin in systemic as well as pyelonephritis infections in mice.
An impurity of Levofloxacin, which is as efficacious as or more efficacious than that with ciprofloxacin in systemic as well as pyelonephritis infections in mice.
An impurity of Levofloxacin, which is as efficacious as or more efficacious than that with ciprofloxacin in systemic as well as pyelonephritis infections in mice.
